US81663L2007
US81663L2007
GeneDx Holdings Corp.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 2.01B EUR | 2.05B EUR | 1.91B EUR | 3.8B EUR |
Enterprise Value | 2.05B EUR | 2.15B EUR | 1.98B EUR | 3.81B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 56.18x | -- | -- | -- |
Price to Sales | 4.42x | 4.5x | 4.3x | 11.17x |
Price to Book | 8.22x | 8.38x | 7.5x | 12.34x |
EV/Revenue | 4.52x | 4.74x | 4.47x | 11.2x |
EV/EBITDA | -60.98x | -- | -- | 241.28x |
Price to FCF (P/FCF) | -- | -- | -- | 372.58x |
EV/FCF | -- | -- | -- | 373.38x |
FCF Yield | -2.37% | -3.7% | -1.5% | 0.27% |